

Initial Directors Interest Notice

Melbourne, Australia and Minneapolis, MN – 6 September 2022: Medibio Limited (“MEB” or “Medibio”) (ASX: MEB) (OTCPINK: MDBIF) attaches an Appendix 3X for Mr David Trimboli following his appointment and notes that the notice was not lodged within the requisite time frame due to an administrative oversight.

In relation to the late lodgement of the attached Appendix 3X, the Company advise as follows:

- a) the initial directors notice is related to the appointment of Mr David Trimboli on 25 August 2022;
- b) the Appendix 3X was lodged late due to an administrative oversight. As soon as the oversight was identified, the attached Appendix 3X was prepared and lodged with the ASX;
- c) the Company and the Directors are aware of their obligations under the ASX Listing Rules 3.19A and 3.19B to provide the necessary information to the Company to meet its disclosure requirements; and
- d) the Company is committed to maintaining a high standard of corporate governance practices and ensuring its compliance with the ASX Listing Rules. The Company has internally reviewed its procedures and processes, implementing procedural improvements.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

For Further information:

Mathew Watkins
Company Secretary
T: +61 3 9692 7222

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Medibio Limited
ABN	58 008 130 336

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Trimboli
Date of appointment	25 August 2022

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

Appendix 3X Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Note: Provide details of the circumstances giving rise to the relevant interest.	
Nil	

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.